

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/165,546	10/02/1998	KNUTH ALEXANDER	LUD5466.4-JE	8012
24972 7:	590 05/23/2002			
FULBRIGHT & JAWORSKI, LLP			EXAMINER	
666 FIFTH AV	_		DECLOUX	, AMY M
NEW YORK,	NY 10103-3198			·
			ART UNIT	PAPER NUMBER
			1644	la
			DATE MAILED: 05/23/2002	. 29

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Advisory Action**

Application No.

Applicant(s) 09/165,546

Alexander et al.

Examiner

DeCloux, Amy

Art Unit



	The MAILING DATE of this communic	cation appears on the cover sheet with the correspondence address
There reject allow	REPLY FILED <u>May 7, 2002</u> FA Ffore, further action by the applicant is requion under 37 CFR 1.113 may only be either FA ance; (2) a timely filed Notice of Appeal (volume with 37 CFR 1.114.	AILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. uired to avoid the abandonment of this application. A proper reply to a final er: (1) a timely filed amendment which places the application in condition for with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in
		ERIOD FOR REPLY [check only a) or b)]
a)	The period for reply expiresn	nonths from the mailing date of the final rejection.
b)	is later. In no event, however, will the statutor	g date of this Advisory Action, or (2) the date set forth in the final rejection, whichever y period for reply expire later than SIX MONTHS from the mailing date of the HEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION.
ex ap se	tension fee have been filed is the date for purposes propriate extension fee under 37 CFR 1.17(a) is ca it in the final Office action; or (2) as set forth in (b) a	136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate of determining the period of extension and the corresponding amount of the fee. The loulated from: (1) the expiration date of the shortened statutory period for reply originally bove, if checked. Any reply received by the Office later than three months after the filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. 🗌	A Notice of Appeal was filed on37 CFR 1.192(a), or any extension there	. Appellant's Brief must be filed within the period set forth in eof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. <b>X</b>	The proposed amendment(s) will not be	entered because:
(a)	$oldsymbol{X}$ they raise new issues that would requ	uire further consideration and/or search (see NOTE below);
(b)	$\square$ they raise the issue of new matter (see	ee NOTE below);
(c)	they are not deemed to place the apprissues for appeal; and/or	olication in better form for appeal by materially reducing or simplifying the
(d)	$\square$ they present additional claims withou	t canceling a corresponding number of finally rejected claims.
		ed claim 74 has been broadened by substituting the pharase "an MHC-Class II , for the phrase MHC Class II HLA-DR53 molecules".
3. 🗌	Applicant's reply has overcome the follo	wing rejection(s):
4. 🗆	Newly proposed or amended claim(s) _ a separate, timely filed amendment can	would be allowable if submitted in celing the non-allowable claim(s).
5. 🗆	The a) ☐ affidavit, b) ☐ exhibit, or c) application in condition for allowance be	request for reconsideration has been considered but does NOT place the ecause:
6. 🗆	The affidavit or exhibit will NOT be consthe Examiner in the final rejection.	idered because it is not directed SOLELY to issues which were newly raised by
7. 🛭		mendment(s) a) Will not be entered or b) Will be entered and an diclaims would be rejected is provided below or appended.
	The status of the claim(s) is (or will be)	as follows:
	Claim(s) allowed: 84 and 88	
	· · · · — — — — — — — — — — — — — — — —	9.86
	Claim(s) rejected: <u>74, 75, 78, 85, and 8</u>	7
8. 🗆		is a approved or b disapproved by the Examiner.
9. 🗌	Note the attached Information Disclosur	re Statement(s) (PTO-1449) Paper No(s) fath \N\sigma\
0. 🗆	Other:	PATRICK J. NOLAN, PH.D. PRIMARY EXAMINER